With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient recruitment to trial design and long-term strategy.

Gri Bio, Inc. ( ($GRI) ) has released its Q2 earnings. Here is a breakdown of the information Gri Bio, Inc. presented to its investors. Gri Bio, ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

The trial aims to assess the regimen over a 90-day period for those with a presumptive diagnosis of the condition.

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and ...

Results of LTR Pharma’s phase I pharmacokinetic (PK) study of SPONTAN, its nasal spray mist to treat erectile dysfunction, ...

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing exp ...